All News

Thrombocytopenia was the most common adverse effect, which was managed through dose reduction.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss research conducted looking to assess the hematology-oncology pharmacist “great migration” from the field.

Isotretinoin exerts dose-dependent inhibition of sebaceous gland function, thereby reducing sebum secretion, which is associated with improvement in nodular acne.

Ken Thorpe, PhD, professor of public health at Emory University and chairman of Partnership to Fight Chronic Disease, discusses legislation that the US House of Representatives recently passed to put greater restrictions on the FDA’s accelerated approval pathway.

After 4 years of treatment with ofatumumab, 78.8% of patients with relapsing forms of multiple sclerosis who continuously received ofatumumab achieved NEDA-3 compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Clinical trial results show durable responses with mosunetuzumab in advanced follicular lymphoma.

Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor that is not yet approved by any regulatory authority.

Jazz Pharmaceuticals announced top-line results from the phase 3 RELEASE MSS1 trial, evaluating nabiximols oromucosal spray in individuals with multiple sclerosis.

Pravastatin sodium (Pravachol) is indicated as an adjunctive therapy to diet to lower the risk of myocardial infarction, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident congenital heart disease.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA; Alison Gulbis, PharmD, BCOP; and Kamakshi Rao, PharmD, BCOP, FASHP, discuss the underlying causes of the hematology-oncology pharmacist great migration from the field.

Surprising turn of events is a strong message to the pharmaceutical industry about the acceptable developmental pathway for this drug class.

Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses methods of accomplishing greater workforce diversity in the field of oncology pharmacy.

Pharmacy Times spoke with Paul Feuerstadt, MD, FACG, AGAF, about the investigative C. difficile treatment RBX2660.

In a sector that relies heavily on opacity, who knows what might be found in the government's inquiry?

Rates of influenza and associated hospitalizations demand late-season vigilance.

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

New data show that after 4 years of treatment, 78.8% of patients who continuously received ofatumumab achieved no evidence of disease activity-3 (NEDA-3) compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Bhavesh Shah, RPh, BCOP, steering committee co-chair of the 2022 ATOPP Summit, discusses the impact of the annual ATOPP summit on the oncology pharmacy field.

The Pharmacy Times® Future of Pharmacy Resource Center is a comprehensive source on the evolution of the pharmacy profession and the growing roles of pharmacists

The Future of Pharmacy initiative is telling the story of where the profession has been and where it is headed.

Sonidegib is a biphenyl carboxamide that blocks the signaling in the hedgehog pathway.

The first step to reducing recurrent C. difficile infections is prevention.

Paul Feuerstadt, MD, FACG, AGAF, discussed the investigative C. difficile treatment RBX2660 and how it impacts time to recurrence.

Nearly 63% of newly diagnosed patients have advanced colorectal cancer, which requires more aggressive treatment and reduces the associated 5-year survival rate.

Ashwagandha KSM-66 (Anxiety & Stress Relief) from Nature’s Bounty is indicated to help manage occasional stress and anxiety.

Many patients with heart failure are hesitant to receive the COVID-19 vaccine due to the fear of myocarditis.

Findings from a study highlight the efficacy and safety of bulevirtide for the treatment of chronic hepatitis delta virus.

Livalo is an HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet in adults with primary hyperlipidemia or mixed dyslipidemia.